Navigation Links
Adeona's Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease is Hot Topic at 2011 California ALS Research Summit
Date:9/30/2011

neurological diseases. For more information on PNA, please visit its website at www.pnaresearch.org.

About the California ALS Research Summit

The California ALS Research Summit is an annual gathering of researchers, investigators, clinicians, biotech companies, government representatives and patient advocates in ALS and related fields in the State of California. The purpose of the Summit to help increase, expedite and promote the amount and level of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease) and related research done in California; and to foster networking, collaboration and cooperation among investigators, their peers and their colleagues to identify, develop and deliver new and effective treatments, ideas and, ultimately, a cure. For more information about the California ALS Research Summit, please visit its website at www.californiaalsresearchsummit.org.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available: reaZin™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and wellZin™, a homeopathic over-the-counter medicine for reducing the duration and symptoms of the common cold. Adeona also operates Adeona Clinical Laboratory,
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
2. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
3. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
4. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
5. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
6. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
7. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
8. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
9. Xanodyne Announces Planned President & CEO Succession
10. Breast Cancer Patient First in Latin America to Receive Treatment Using Elekta VMAT Planned with Monaco Software
11. Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... and Tobago , July 25, 2014 /PRNewswire/ ... Trinidad & Tobago Ministry of Health approved the ... that significantly increases the cure rate from Hepatitis ... with the genotype 1 virus. Telaprevir is available ... trade brand INCIVO®. Photo - ...
(Date:7/25/2014)... July 25, 2014  Acsis Inc., the market ... serialization solutions, has recently posted an article, ... current and future needs for companies, extended supply ... supply chain model no longer work today.  The ... the growth of mobile technology, machine to machine ...
(Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... by March of Dimes Grantee Offers Hope for Treatment ... new gene-based,technique has successfully prevented a rare craniofacial birth ... the same disorder, according,to new research funded in part ... is being published in the journal Nature Medicine,demonstrates the ...
... /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: ... in the People,s Republic of China ("PRC"), ... in the development of,isosorbide mononitrate sustained release ... and treatment of angina., Based on ...
Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
(Date:7/28/2014)... 28, 2014 According to the Drama Method ... relationship guide that helps women easily get the attention of ... Vkool reveals in its review that this book can teach ... their man. The book also instructs them how to conquer ... in its Drama Method review that this book is divided ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release of ... new book, DOC X MD Funny Feelings translates ... style with humor and medical accuracy. The book is creatively ... answers to those age-old questions that most folks are embarrassed ... do mosquitoes bite some and not others? Why do folks ...
(Date:7/27/2014)... Recently, Wdsshop.de, a reliable online supplier of women’s ... prom dresses on its website. Now, all these ... 58% off. , “We are pleased to add the new ... specially created for those who are in need of fashionable ... in style. I think our clients will love them. Ladies, ...
(Date:7/27/2014)... shown that a powerful drug given at the time ... early risk of rejection, but that it also allows ... used after the operation. , The key results are ... the World Transplant Congress in San Francisco today. They ... the powerful combinations of treatments used to prevent early ...
(Date:7/27/2014)... why medication to treat asthma and pneumonia can become ineffective. ... that drugs widely used to treat lung diseases work with ... which is caused by an infection, affects around 1 in ... young children, the elderly, smokers and those with an underlying ... the UK are affected by asthma and the NHS spends ...
Breaking Medicine News(10 mins):Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Drugs used to treat lung disease work with the body clock 2
... this Valentine,s Day and give the friends and family ... gift that will satisfy,their sweet tooth, warm their heart ... new Organic Chocolate Single Serve is a deep chocolate,nectar ... all of the,fat, cholesterol and calories," said Pam Dietz, ...
... A new company has joined the fight against MRSA ... have launched a new company, Inspiralis Ltd, based around ... enzymes that help DNA molecules to unravel and wind ... , DNA becomes tangled as a result of ...
... Nearly 90,000 Annual ... ... provider of,point-of-care charge capture technologies, today announced that its,customer, the ... Infusion Services Module., The Module, an extension of MedAptus, ...
... of Men With Erectile Dysfunction Are Smokers, NEW ... image and attractiveness, it does the exact opposite when ... According to recent studies, 60-percent of all men who ... partners burning,for more passion. In an effort to dramatically ...
... of the Cancion(R) System in Patients ... Hospitalized with Heart Failure, ... products company developing and marketing devices to,treat heart failure, announced ... Breaking Clinical Trial presentation at the,upcoming annual American College of ...
... Noyes announced today that,the firm represented The Riverside Company ... to Halyard Capital. The management team will,continue to have ... transaction,were not disclosed., "This is an excellent match ... winning healthcare and information franchise," said,Tom O,Connor, the Berkery ...
Cached Medicine News:Health News:Give Vitasoy's 'Liquid Love' for Heart Month! 2Health News:DNA with a twist: New company to search for cancer drugs and antibiotics 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 3Health News:The Best Way to Stoke Your Valentine's Fire: Don't Light Up 2Health News:Orqis(R) Medical's MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 3
... incubators hold rotators and agitators ... can be set at 22C ... to 40C (59F to 104F). ... top to bottom. Recorder is ...
... Platelet incubators hold rotators and ... temperature can be set at ... 15C to 40C (59F to ... from top to bottom. Recorder ...
This model of bench top refrigerated incubator has been designed to suit the TPS-32 platelet shaker....
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: